| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed81c6ea93edb0d59f9c35d7a9c6cd52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86389ecc76a8360d7a31596b74c75d42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_034805ae841c6ae6e101b2cb03295cde |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate |
2003-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0743d0422dd7176a0cea0c00a7b23f94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe615a544b62454f21e618cc26174d9 |
| publicationDate |
2004-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004041187-A2 |
| titleOfInvention |
Compositions and methods for transdermal oxybutynin therapy |
| abstract |
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2772252-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8920392-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2905601-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10449173-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9259388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107303288-A |
| priorityDate |
2002-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |